NKGEN BIOTECH News

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech, Inc. (Nasdaq: NKGN) today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

GlobeNewswire17:05 ET

10-Q: Quarterly report

SEC announcementMay 20 17:02 ET · Announcements

Top Midday Gainers

MultiMetaVerse Holdings (MMV) said Monday that it signed a non-binding term sheet to acquire 100% of Bowong Technology and its subsidiaries for an undisclosed amount. Shares surged 135% as intraday tr

MT NewswiresMay 20 14:00 ET

Trending Stocks Today: MultiMetaVerse Shoots up 136.96%

May 20th - US stocks trending in regular trading hours.Gainers: $MultiMetaVerse(MMV.US)$ shoots up 136.96% to $1.4 with a turnover of $192.18 million. $GT Biopharma(GTBP.US)$ surges 150.32% to $7.81 w

moomoo NewsMay 20 14:00 ET

Sector Update: Health Care Stocks Ease Monday Afternoon

Health care stocks were lower Monday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB) rose

MT NewswiresMay 20 13:59 ET

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.

BenzingaMay 20 13:28 ET

SCPX, XTIA and CRVO Among Mid-day Movers

Seeking AlphaMay 20 13:12 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersGT Biopharma (NASDAQ:GTBP) shares rose 173.5% to $8.53 during Monday's regular session. The market value of their outstanding shares is at $11.7 million. As per the press release, Q1 earnings c

BenzingaMay 20 12:31 ET

Nasdaq Surges 100 Points; Wix.com Shares Jump Following Q1 Results

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.The Dow traded up 0.04% to 40,020.16 while the NASDAQ rose 0.64% to 16,792.13. The S&

BenzingaMay 20 12:03 ET

PTC Therapeutics, Oragenics, GT Biopharma Among Healthcare Movers

Seeking AlphaMay 20 10:00 ET

Why NKGen Biotech Stock Is Moving Higher Monday

NKGen Biotech Inc (NASDAQ:NKGN) shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer's disease.What To Know: NKGen announced tha

BenzingaMay 20 09:17 ET

NKGen Shares Soar After SNK01 Cleared for Phase 2

By Dean Seal Shares of NKGen Biotech jumped after the company was cleared to progress its SNK01 cell product for the treatment of Alzheimer's disease into its next phase of clinical development. The

WSJMay 20 09:11 ET

Market-Moving News for May 20th

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluationNKGN: 81% | NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 T

BenzingaMay 20 08:37 ET

Express News | NKGen Biotech Shares Rise 46.4% Premarket After Clearance to Start Mid-Stage Study on Alzheimer's Disease Cell Therapy

ReutersMay 20 08:15 ET

Express News | NKGen Biotech Shares Are Trading Higher After the Company's SNK01 NK Cell Therapy Was Cleared to Begin a Phase 2 Trial in Alzheimer's Disease

BenzingaMay 20 08:08 ET

Express News | NKGen Biotech Announces Its Safety Review Committee Has Cleared Co.'s SNK01 To Progress Into Phase 2 Development In Alzheimer's Disease

BenzingaMay 20 08:07 ET

Express News | NKGen Biotech Inc: Advances Snk01 Into Phase 2 in Moderate Alzheimer's Disease; First Patient Enrolled in Phase 2 Expected in Q2 2024

ReutersMay 20 08:05 ET

NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease

NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced that its Safety Review Committee has cleared the Company's cryopreserved autologous, expanded and enhanced SNK01 to progress into Phase 2 clinical development.

Globe NewswireMay 20 08:05 ET

Express News | NKGen Biotech’s Snk01 Nk Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease

ReutersMay 20 08:05 ET

Express News | NKGen Biotech Announces Upcoming Presentation on Autologous Nk Cell Therapy at the 5TH International Cell & Gene Therapy China Summit & Exhibition

ReutersMay 16 08:05 ET